Johnson Pharmacare Ltd

Johnson Pharmacare Ltd has announced the closure of its trading window for all designated persons and connected individuals. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be closed from July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The exact date for the declaration of these results will be communicated later. This action is a standard procedure to prevent potential insider trading during the period leading up to financial result announcements.

Johnson Pharmacare Ltd has submitted its audited financial results for the quarter and full year ended March 31, 2026. The results were approved by the Board of Directors during a meeting held on May 27, 2026. An Independent Auditor's Report from C.A. Vineet Gupta was also presented and placed before the Board. The filing includes detailed statements of assets and liabilities, as well as the statement of audited financial results compliant with IND-AS.

Johnson Pharmacare Ltd. has disclosed that Related Party Transaction (RPT) provisions are applicable to the company. However, for the year ended March 31, 2026, the company did not enter into any transactions with related parties as defined under applicable accounting standards and SEBI regulations. Therefore, the disclosure of Related Party Transactions is not applicable, as per SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662.

Johnson Pharmacare Ltd's board of directors approved the audited financial results for the quarter and financial year ended March 31, 2026, along with the Independent Auditors Report. The board also took note of the resignations of Mr. Rajendra Prasad (Non-Executive Director) and Mr. Umesh Kumar (Executive Director), both effective April 17, 2026. The meeting was held on May 27, 2026.

Johnson Pharmacare Ltd has scheduled a Board of Directors meeting on May 27, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The trading window has been closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the results.

The Board of Directors of Johnson Pharmacare Ltd, in a meeting held on April 17, 2026, approved the resignations of two key directors. Mr. Rajender Parsad (DIN: 10871533) resigned as an Additional & Non-Executive Director, and Mr. Umesh Kumar (DIN: 07015921) resigned as an Additional & Executive Director. Both resignations are effective from April 17, 2026, and were attributed to personal and unavoidable reasons, with no other material reasons confirmed by the directors.

Johnson Pharmacare Ltd's Board of Directors, in a meeting held on April 17, 2026, approved two key appointments. Mr. Nand Kishore Ray (DIN: 11626638) has been appointed as an Additional Non-Executive & Non-Independent Director, effective April 17, 2026. Concurrently, Mr. Dheeraj Kumar (DIN: 11666616) was appointed as an Additional Executive Director, also effective from April 17, 2026. Both individuals have confirmed they are not debarred from the capital market by SEBI or any other authority.

Johnson Pharmacare Ltd announced significant changes to its Board of Directors, effective April 17, 2026. The company appointed Mr. Nand Kishore Ray (DIN: 11626638) as an Additional Non-Executive & Non-Independent Director and Mr. Dheeraj Kumar (DIN: 11666616) as an Additional Executive Director. Concurrently, Mr. Rajender Parsad (DIN: 10871533) resigned from his position as an Additional & Non-Executive Director, and Mr. Umesh Kumar (DIN: 07015921) resigned as an Additional & Executive Director, both citing personal and unavoidable reasons. The company confirmed no other material reasons for their resignations.

Johnson Pharmacare Ltd has announced the closure of its trading window for all Designated Persons and specified Connected Persons. The closure is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation 2015 and the Company’s Code of Conduct for Prevention of Insider Trading. The trading window will remain closed from 1st April, 2026, till the completion of 48 hours after the declaration of audited Financial Results for the quarter and year ended on 31st March, 2026. The date of consideration of the audited Financial Results will be intimated in due course.

Johnson Pharmacare Ltd. has appointed Ms. Parul Agrawal (DIN: 11268580) as an Additional Non-Executive & Independent Director, effective from 13th February, 2026. Ms. Agrawal is not related to the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other authority. The appointment was approved during the Board of Directors meeting held on 13th February, 2026.